ANI Pharmaceuticals Inc
- Last sale
- Nov 12, 2026 · -0.49%
- Market cap
- $1.60B
- 22.49M shares
- Filings
- 1,047
Q3 2026+43.8% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+18,922.8% FY25 yoy
Q3 2026derived+258.7% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+97.1% FY25 yoy
- $1.60B
- 13.7×
- 1.5×
- 2.5×
- 12.86%
- 0.00%
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $883,366,000 | reported | |
| FY 2024 | 2024-12-31 | $614,376,000 | reported | |
| FY 2023 | 2023-12-31 | $486,816,000 | reported | |
| FY 2022 | 2022-12-31 | $316,385,000 | reported | |
| FY 2021 | 2021-12-31 | $216,136,000 | reported | |
| FY 2020 | 2020-12-31 | $208,475,000 | reported | |
| FY 2019 | 2019-12-31 | $206,547,000 | reported | |
| FY 2018 | 2018-12-31 | $201,576,000 | reported | |
| FY 2017 | 2017-12-31 | $176,842,000 | reported | |
| FY 2016 | 2016-12-31 | $128,622,000 | reported | |
| FY 2015 | 2015-12-31 | $76,322,000 | reported | |
| FY 2014 | 2014-12-31 | $55,970,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.16M | $12.21M | $13.37M | — | 22.49M sh | +6.6% | 7.8% |
| FY2024 | $1.63M | $10.96M | $12.58M | — | 21.11M sh | — | 26.3% |
| FY2023 | $1.63M | $4.99M | $6.61M | — | — | — | 6.0% |
| FY2022 | $1.63M | $1.96M | $3.58M | — | — | — | — |
| FY2021 | $190.00K | $890.00K | $1.08M | — | — | — | 141.2% |
Segments
LineFY2025ShareChange
Rare Disease and Brands$483.93M55%+64.4%
Generics and Other$399.43M45%+24.8%
Generics, Established Brands and Other———
Rare Disease———
Total$883.37M
Pharmaceutical preparations
ANI Pharmaceuticals Inc is the 38th largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
LEGNLegend Biotech Corp$1.0B64.0%28.8%$3.4BMDGLMadrigal Pharmaceuticals, Inc.$958.4M432.1%30.1%$9.9BIONSIonis Pharmaceuticals Inc$943.7M33.8%40.4%$4.5B
ANIPANI Pharmaceuticals Inc (this company)$883.4M43.8%8.9%$1.6B
HRMYHarmony Biosciences Holdings, Inc.$868.5M21.5%18.3%$2.0BTLXTelix Pharmaceuticals Ltd$803.8M55.6%0.9%—COLLCollegium Pharmaceutical, Inc$780.6M23.6%8.1%$776.1MCORTCorcept Therapeutics Inc$761.4M12.8%13.1%$8.1BEBSEmergent BioSolutions Inc.$742.9M28.8%7.1%$302.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
ANI Pharmaceuticals Inc · CIK 1023024 · Engraved from SEC EDGAR